Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1

Vivian Adamski1 · Kirsten Hattermann2 · Carolin Kubelt1 · Gesa Cohrs1 · Ralph Lucius2 · Michael Synowitz1 · Susanne Sebens3 · Janka Held-Feindt1

Received: 9 December 2019 / Revised: 7 April 2020 / Accepted: 9 April 2020 / Published online: 28 April 2020 © The Author(s), under exclusive licence to Springer Nature Limited 2020. This article is published with open access

Abstract
Glioblastoma multiforme (GBM) is a malignant brain tumor that evades therapy regimens. Since cellular dormancy is one strategy for surviving, and since chemokines determine the environmental conditions in which dormancy occurs, we investigated how chemokines affect temozolomide (TMZ)-promoted cellular dormancy entry and exit in GBM cells. TMZ administration over ten days promoted cellular dormancy entry, whereas discontinuing TMZ for a further 15 days resulted in resumption of proliferation. Co-administration of a chemokine cocktail containing CXCL12, CXCL16, and CX3CL1 resulted in both delayed entry and exit from cellular dormancy. A microarray-based transcriptome analysis in LN229 GBM cells revealed that cellular dormancy entry was characterized by an increased expression of CCL2 and SAA2, while THSD4, FSTL3, and VEGFC were upregulated during dormancy exit. Co-stimulation with the chemokine cocktail reduced upregulation of identified genes. After verifying the appearance of identified genes in human GBM primary cultures and ex vivo samples, we clarified whether each chemokine alone impacts cellular dormancy mechanisms using specific antagonists and selective CRISPR/Cas9 clones. While expression of CCL2 and SAA2 in LN229 cells was altered by the CXCL12-CXCR4-CXCR7 axis, CXCL16 and CX3CL1 contributed to reduced upregulation of THSD4 and, to a weaker extent, of VEGFC. The influence on FSTL3 expression depended on the entire chemokine cocktail. Effects of chemokines on dormancy entry and exit-associated genes were detectable in human GBM primary cells, too, even if in a more complex, cell-specific manner. Thus, chemokines play a significant role in the regulation of TMZ-promoted cellular dormancy in GBMs.

Introduction
Glioblastoma multiforme (GBM) is a disease with a poor prognosis due to resistance to chemotherapy and radiotherapy [1]. Evolutionary processes within the heterogeneous tumor mass give rise to specialized tumor cell subpopulations [2–6], which adapt to their microenvironment and manage to survive therapeutic strategies.

One strategy by which tumor cells escape treatment effects is entering a dormant state which might occur via two mechanisms: tumor mass dormancy and cellular dormancy. In tumor mass dormancy tumors remain occult, do not expand in size for a long time, which might also occur in minimal residual disease after surgical removal or treatment of the tumor [7–13]. In tumor mass dormancy, there is a balance of proliferating and dying tumor cells which is achieved by and dependent on immune cells in the direct proximity (immunesurveillance) or an insufficient angiogenic potential. In contrast, during cellular dormancy solitary tumor cells undergo a temporary quiescence which is based on a growth arrest which can be promoted, e.g., by chemotherapy [7–13].
The existence of dormancy was proven in GBMs [10–17] and is characterized by the upregulation of a specific dormancy-associated gene set [17]. Dormancy contributes to a poor therapy outcome in GBMs [18], and the occurrence of a therapy-driven plasticity of GBM cells towards a predominantly drug-promoted cellular dormant...
GBM cells and investigated the impact of TMZ-promoted cellular dormancy entry and exit in human glioma progression. A complex chemokine-signaling network is involved in this important tumor biological phenomenon.

Results

TMZ-treated LN229 GBM cells are a reliable in vitro model for investigating cellular dormancy entry and exit and the influence of chemokines on these processes

In accordance with our previous results [19], we were able to induce drug-promoted cellular dormancy entry in LN229 cells after ten days of TMZ-application. LN229 cells are known to be partially TMZ-sensitive, probably due to a low O6-methylguanine-DNA methyltransferase (MGMT) expression [34, 35]. TMZ is a common GBM chemotherapeutic which, besides other mechanisms, is able to induce cellular quiescence by promoting cell cycle-arrest [36]. Indeed, as previously shown by cytotoxicity analysis [19], most LN229 cells died during a continuous ten-day TMZ-stimulation, however, some cells survived this treatment. These cells mainly exhibited an enlarged morphology with large nuclei [19] and were also characterized by DiO-retention and larger intracellular phospho-p38 amounts in relation to phospho-p42/44 signals (Fig. 1a, b), as shown previously [19] and in line with dormancy criteria described in the literature [37, 38]. In addition, TMZ-treated LN229 cells were characterized by a negative staining for the proliferation marker Ki-67 (Supplementary Fig. 1). Altogether, these results clearly indicate the acquisition of a cellular dormant phenotype in TMZ-treated surviving LN229 cells.

After 15 days of TMZ-withdrawal, we observed a recovery of the LN229 cells, evidenced by the successive appearance of DiO-negative, as well as the occurrence of a phospho-p38/phospho-p42/44 ratio similar to DMSO controls. Overall, these findings strongly support the view that LN229 cells undergo a TMZ-promoted cellular dormant stage which is reversible after TMZ-withdrawal (Fig. 1a, b). Interestingly, applying the chemokine cocktail during TMZ-treatment and the TMZ-free recovery period reduced both cellular dormancy entry and exit. The numbers of DiO-positive (dormancy entry), as well as DiO-negative (dormancy exit) LN229 cells were lower than in experiments without chemokines. Furthermore, the phospho-p38/phospho-p42/44 ratios decreased during cellular dormancy entry and were slightly increased during cellular dormancy exit compared with respective experiments without chemokines. Both mRNA and protein expression of CXCR4 and CXCR7, known chemokine receptors mediating CXCL12 signals, as well as of the chemokine ligands CXCL16 and CX3CL1 were induced in LN229 cells during TMZ-treatment (Fig. 1d, e). The chemokine receptors CXCR6 and CX3CR1, which are usually known to mediate CXCL16 and CX3CL1 signals, were not expressed in the LN229 cells (data not shown). However, via a recently
published mechanism known as “inverse signaling” [32], soluble CXCL16 and CX3CL1 molecules are able to bind to their transmembrane counterparts resulting in the induction of intracellular signal cascades and cellular responses. In comparison, neither induction of cellular quiescence nor regulation of intracellular signal cascades, or CXCR4, CXCR7, CXCL16, or CX3CL1 expression were altered in TMZ-treated T98G cells (Fig. 1c, d). These results are in accordance with previously published data, which show that T98G cells are characterized by a pronounced TMZ resistance, probably due to a strong MGMT expression [34, 35]. However, it should be clearly stated that T98G cells cannot actually be called “non-dormant” since they are able to induce dormant tumors in vivo with proliferation potentials similar to native, non-drug-treated T98G cells in vitro [12, 17]. Since we particularly aim to investigate the impact of chemokines on entry and exit of TMZ-promoted cellular dormancy, it should be kept in mind that the results of the different cell lines will compared only with regard to this specific aspect.

**Chemokines affect several genes associated with TMZ-promoted cellular dormancy entry and exit**

To analyze the influence of chemokines on LN229 gene expression during drug-promoted cellular dormancy entry and exit, a microarray-based transcriptome analysis was performed using an ArrayXS human 8 × 60 K microarray, and Venn diagrams were prepared for cellular dormancy entry and exit (Fig. 2). Complete gene lists including log2FC and p-values of different Venn areas are given in Supplementary Tables 1 and 2.

1512 genes were regulated in LN229 cells during TMZ-promoted cellular dormancy entry. 499 genes were regulated to significant extents when the cellular dormant state was induced by TMZ with additional chemokine application, and 1014 genes were regulated in both groups. Regarding cellular dormancy exit, 1381 genes were differentially expressed in the TMZ versus DMSO recovery group, 3834 in the TMZ versus DMSO plus chemokines recovery group, and 1173 were regulated in both groups. To narrow down the number of interesting genes, we defined three conditions: 1. genes have to be regulated during TMZ-promoted cellular dormancy entry or exit (1512 and 1381 gene groups, respectively) with at least a log2FC = 2 value; 2. when comparing log2FC values of TMZ-promoted cellular dormancy entry-associated or exit-associated genes with those values resulting after additional chemokine application, chemokines should regulate the distinct genes or not all (dormancy entry: 1014 and/or 1512 gene groups; dormancy exit: 1173 and/or 1381 gene groups); and 3. only known genes were considered that were expressed to clearly detectable extents after TMZ-treatment and that could also be analyzed at the protein level. According to these restrictions, we decided to exemplarily investigate the genes CCL2 and SAA2 coding for the CC-chemokine ligand 2 and the serum amyloid A protein 2 for cellular dormancy entry, and the genes FSTL3, VEGFC, and THSD4 coding for the follistatin-related protein 3, the thrombospondin type 1 domain containing 4 protein, and the vascular endothelial growth factor C for cellular dormancy exit.

**Validation of the significance of TMZ-promoted cellular dormancy entry-associated and exit-associated genes and impact of chemokines**

To confirm the results of the transcriptome analysis, we used our above described GBM in vitro model and analyzed the data both at the mRNA and protein level. CCL2 and SAA2 were indeed expressed in LN229 cells (Fig. 3 top, left diagram), and their mRNA and protein expression was clearly induced during TMZ-promoted cellular dormancy entry, whereas this induction was not as prominent when
cellular dormancy entry was induced with TMZ and additional chemokine stimulation (Fig. 3 top). Although T98G cells did not respond to TMZ-treatment with induction of a cellular dormant state, basal CCL2 and SAA2 expression was also confirmed in these cells (Fig. 3 bottom, left diagram). However, in these cells no TMZ-promoted regulation of CCL2 and SAA2 expression was detectable, and no influence of chemokines on CCL2 and SAA2 expression was observed (Fig. 3 bottom). Protein signals were below the detection level in T98G cells due to the absent TMZ-promoted induction of CCL2 and SAA2 expression.

When investigating the cellular dormancy exit, both mRNA expression and protein synthesis of cellular dormancy exit-associated molecules FSTL3, THSD4, and VEGFC were clearly induced in TMZ-treated LN229 cells, and this induction was diminished by additional chemokine stimulation.
application (Fig. 3 top). FSTL3, THSD4, and VEGFC were detected both at the mRNA and the protein level in T98G, as well. However, no convincing neither TMZ-promoted nor chemokine-induced regulation of these genes and proteins was observed (Fig. 3 bottom).

In order to verify the appearance and distribution of identified genes in a broader group of human brain tumor samples, mRNA expression of exemplary cellular dormancy-associated genes was analyzed in human glioma tissues of various malignancy grades, as well as in GBM primary cultures. With some exceptions concerning SAA2 and VEGFC expression, mRNAs of all genes were well detectable in GBM primary cultures, solid astrocytoma WHO II, III, and GBM samples (Fig. 4a, b). Interestingly, VEGFC and THSD4 were expressed significantly less in GBMs than in astrocytoma II samples. Furthermore, all proteins were abundantly found in human GBM tissues by ex vivo immunofluorescence staining (Fig. 4c). Interestingly, CCL2 and SAA2, as well as THSD4 and FSTL3 showed partial co-staining with each other, while VEGFC could only be detected in the absence of THSD4 or FSTL3. CCL2-positive cells showed pronounced co-staining with VEGFC, and partial co-staining with THSD4, but no co-staining with FSTL3. In contrast, SAA2 almost exclusively co-stained with FSTL3 and THSD4 but only partially with VEGFC.

**Identified drug-promoted cellular dormancy entry-associated and exit-associated gene expression is modulated by single chemokines in a distinct manner**

To clarify whether individual chemokines impact on drug-promoted cellular dormancy mechanisms, the influence of each chemokine alone and co-administered with TMZ during cellular dormancy entry and exit was analyzed in LN229 cells. Furthermore, chemokine signaling was abolished by CRISPR/Cas9 deletion of CXCR7, CXCL16, or CX3CL1, or by co-stimulation with AMD3100, a specific inhibitor of CXCR4 signaling [39]. Successful transfection was confirmed by the chemokine cocktail. With exception of VEGFC for 118/14, expressed all identified cellular dormancy-associated genes (Fig. 4a). Interestingly, expression of CXCR4, CXCR7, CXCL16, and CX3CL1 was heterogeneously regulated in primary cells after ten days of TMZ-treatment (Fig. 6 left diagrams). Further, not all identified dormancy entry-associated and exit-associated genes were upregulated after TMZ-promoted cellular dormancy entry or recovery, respectively. This more complex situation was also reflected by the influence of the chemokine cocktail on the expression of the identified genes (Fig. 6). Whereas CCL2 expression was suppressed by TMZ irrespectively of additional chemokine stimulation, SAA2 upregulation could be confirmed in both GBM cells and was efficiently inhibited by the chemokine cocktail. With exception of VEGFC in 118/14 cells, all dormancy-exit associated genes were clearly upregulated in primary GBM cells.
after TMZ-recovery. Whereas THSD4 upregulation was decreased in 116/14 cells by additional chemokine application, VEGFC and FSTL3 expression in 116/14 cells was further increased by the chemokine cocktail. Thus, this cell type-specific regulation of CXCR4,
CXCR7, CXCL16, and CX3CL1 in human primary GBM cells resulted in a specific influence on the TMZ-regulated expression of cellular dormancy entry-associated and exit-associated genes.

**Discussion**

Dormancy has been termed one of two prerequisites for life and plays a fundamental role in all stages of tumor progression. The regulation of cellular dormancy is crucial for the survival of tumor cells, enabling them to enter a state of quiescence and subsequently reactivate upon pharmacological stimulation. The study presented here aimed to understand the role of chemokines in the regulation of cellular dormancy in glioblastoma multiforme (GBM) cells.

The research focused on the impact of individual chemokines, such as CXCR7, CXCL16, and CX3CL1, on the expression of genes associated with cellular dormancy. The investigators used CRISPR/Cas9 knock-out in LN229 cells to assign identified gene regulations to the impact of an individual chemokine. Successful transfection of the CRISPR/Cas9-transfected LN229 clones was confirmed by immunofluorescent staining and qRT-PCR analysis.

The cells were then stimulated with TMZ or DMSO, with or without 2 nM of the respective chemokine. Pretreated cells were incubated for an additional 15 days without TMZ but with 2 nM of the respective chemokine. The gene expression of CCL2, SAA2, THSD4, FSTL3, and VEGFC was assessed by qRT-PCR after ten and 25 days. The data are shown as n-fold gene regulation with additional chemokine stimulation compared to TMZ-treatment alone.

Statistical analysis of CRISPR/Cas9 transfection was performed with unpaired, two-sided Student’s t-test. Differences resulting from stimulation of native LN229 cells with each chemokine were analyzed by repeated one-way ANOVA with Dunnett’s multiple comparison post hoc test, and regulation in CRISPR/Cas9-transfected cells due to additional chemokine administration, and superordinate comparisons between different clones were tested by paired, two-sided Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001.
progression [8, 40]. Whereas in tumor mass dormancy, proliferation of tumor cells is balanced by cell death, cellular dormancy is described as a reversible quiescent cellular stage. Anti-cancer therapies promote entry into dormancy, and the local microenvironment seems to be a critical endogenous determinant for entry into and exit from dormancy [41]. In fact, chemokines as inflammatory mediators affect cancer dormancy [42–44]. Distinct chemokines, in particular CXCL12, CXCL16, and CX3CL1, are essential for tumor preservation with their autocrine or paracrine signaling promoting anti-apoptotic effects or proliferation of many tumor types including GBMs [27–33].

We showed that TMZ promoted cellular dormancy in GBM cells confirming previously published results [19], while removal of TMZ led to initiation of proliferation. However, entry into cellular dormancy depended on the responsiveness of the individual glioma cell line to TMZ. Most GBM cells expressed the chemokine receptors and ligands that are necessary for signaling [27–33], and those were also significantly upregulated in TMZ-sensitive LN229 GBM cells by TMZ-stimulation.

Bruyère et al. also described a possible influence of long-term TMZ-treatment on chemokine and chemokine receptor expression [45]. Complementing these results, our model with co-administration of the chemokines CXCL12, CXCL16, and CX3CL1 resulted in LN229 GBM cells in both delayed entry and exit from TMZ-promoted cellular dormancy. This is illustrated by the influence on the expression of several genes. However, although drug-treatment induced identified dormancy-associated genes in human GBM primary cells, too, the situation in GBM primary cells seems to be more complex. Chemokines were able to regulate the expression of these genes, but in a more cell-specific manner probably caused by a more heterogeneous expression and regulation of chemokine ligands and receptors in these primary tumor cells having undergone less selection during cell culture compared to established GBM cell lines. Interestingly, the impact of cyto- and chemokines on dormancy-related pathways has been partly studied in other tumors. De Cock et al. [46] showed that inflammation triggered the escape of metastatic breast cancer cells from a dormant phase, and two other studies demonstrated that the recovery of dormant breast cancer cells depended on IL-6, IL-8, and TGF-ß1 signaling [43, 47]. Further, downregulation of CXCR4 in metastatic breast cancer cells was linked to restrained proliferation [44]. Furthermore, we showed that TMZ-promoted cellular dormancy entry-associated and exit-associated gene expression was modulated by individual chemokines in a distinct manner. The expression of the cellular dormancy entry-associated genes CCL2 and SAA2 in LN229 cells was determined by qRT-PCR after ten and 25 days of stimulation (exact numbers of biological replicates are shown in the figure, n = 2 technical replicates, respectively). Statistical analysis of gene regulation by TMZ-stimulation was performed by repeated two-way ANOVA with Bonferroni’s multiple comparison post hoc test. The effects with and without chemokines were analyzed by paired, two-sided Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001. Regulation of chemokine ligand and receptor gene expression was analyzed by paired, two-sided Student’s t-test. *p < 0.05. DMSO, dimethyl sulfoxide; Rec: recovery; TMZ, temozolomide.

**Fig. 6** Influence of chemokines on TMZ-promoted cellular dormancy entry-associated and exit-associated gene expression in human GBM primary cultures. Human GBM primary cells 116/14 and 118/14 were treated with 500 µM TMZ or 0.5% (v/v) DMSO, respectively, with or without a chemokine mix containing 2 nM CXCL12, CXCL16, and CX3CL1 for ten days followed by a further 15 days without TMZ but with chemokine stimulation. Regulation of the respective chemokine receptors and ligands was investigated by qRT-PCR after ten days of TMZ-treatment, regulation of identified cellular dormancy entry-associated and exit-associated genes was
altered by CXCL12 pointing to a relevance of the CXCL12-CXCR4-CXCR7 signaling pathways.

CCL2, also known as monocyte chemotactic protein 1 (MCP1), is a chemokine that is widely expressed in the brain, while SAA2 is an acute phase protein with cytokine-like properties that promotes neutrophil adhesion to endothelial cells during inflammation [48]. Indeed, Oh et al. [49] observed an interaction of CCL2 and CXCL12 in glioma cells. Goffart et al. [50], as well as Hattermann et al. [28] associated the CXCL12-CXCR4 signaling axis with an increased resistance of GBM stem cells, and CCL2 expression correlated with the progression of GBMs [51–54]. Here, the CCL2-CCR2 signaling axis plays a dual role in mediating early tumor immune surveillance and sustaining growth and progression of established neoplasms [55]. In addition, a senescence-associated gene signature including CCL2 was associated with a poor prognosis in human gliomas [56].

SAA2 is known to be regulated by, and is, itself able to sustain inflammatory conditions in the brain, which in turn support resistance to TMZ and induce stem cell marker expression in GBM cells in vivo [54, 57]. Since dormancy and stem cell characteristics are closely connected [19], this may support the hypothesis that SAA2 is involved in a drug-promoted cellular dormancy entry.

Interestingly, the expression of both SAA2 and CCL2 is regulated by members of the mitogen-activated protein (MAP) kinase family, especially under inflammatory conditions. As described, SAA2 transcription was induced by SAF-1, a zinc finger transcription factor that was activated by a number of inflammatory agents. SAF-1 was activated via MAP kinase-regulated phosphorylation [58]. Induction of CCL2 expression via inflammatory conditions seemed to be controlled by the interplay of c-jun N-terminal kinase (JNK), p38, and to a lesser extent of extracellular signal-regulated kinase (ERK) [59]. Since it is well known that CXCL12 activates members of the MAP kinase family in gliomas via its G-protein-coupled receptors CXCR4 and CXCR7 [22, 27, 28], it seems obvious that CXCL12 regulated CCL2 and SAA2 expression during cellular dormancy entry via these pathways.

On the other hand, CXCL16 and CX3CL1 both affected the alteration of TMZ-promoted cellular dormancy exit in LN229 cells as shown by their impact on the expression of THSD4 and, to some extent, of VEGFC. However, significant FSTL3 regulation required stimulation with all three chemokines.

Indeed, to escape angiogenic dormancy, the tumor undergoes an angiogenic switch leading to enhanced release of proangiogenic factors [9]. Besides its proangiogenic function, VEGFA promoted tumor dormancy reversal [52]. Thus, it can be speculated that VEGFC plays a similar role. Interestingly, CX3CL1 is a regulator of angiogenesis, and stimulation of macrophages with CX3CL1 resulted in a reduced VEGFA expression [60]. VEGFC expression is regulated via the PI3K-AKT-mTOR signaling pathway [61]. Since CXCL16 was able to activate Akt via inverse signaling mechanisms in brain tumors [62], the PI3K-AKT signaling pathway might be involved in the regulation of VEGFC expression via CXCL16, and probably via CX3CL1, during cellular dormancy exit.

Concerning the role of THSD4 in cellular dormancy exit, repression of thrombospondin-1 activity induced angiogenesis and proliferation in persistent tumors [63]. THSD4 is a protease, also known as an ADAM with thrombospondin motifs-like protein 6 (ADAMTS6) that was upregulated during GBM recovery. However, other ADAMs with thrombospondin motifs (ADAMTS4, ADAMTS5) positively impacted the proliferation of glioma cells in vitro and potentially promoted their invasion by cleavage of brevican, a major component of brain tissue [64]. Cohen et al. [65] demonstrated that THSD4 expression was regulated by the GATA binding protein 3 (GATA3). This protein belongs to a family of tissue specific transcription factors and is able to transactivate its target genes [65]. Chemokines were able to inhibit the expression of GATA3 [66]. Thus, a reduction of GATA3 expression may be involved in CXCL16-regulated or CX3CL1-regulated inhibition of THSD4 expression in gliomas.

Apart from this, upregulation of FSTL1, a homolog of FSTL3, increased the TMZ resistance of GBM cells [67] and was correlated with proliferation and colony formation [68]. FSTL3 is a secreted glycoprotein involved in the regulation of various biological effects through its binding to members of the TGFβ superfamily. TNFα has been shown to activate FSTL3 expression at the transcriptional level through a responsive element which binds the transcription factor nuclear factor κB (NF-κB) [69]. Furthermore, TGFβ promoted the effect of TNFα on FSTL3 expression [69]. Since the kinase Akt regulates the transcriptional activity of NF-κB [70], and chemokines are able to regulate Akt [62], Akt-NF-κB-mediated signaling is probably involved in the regulation of FSTL3 expression by chemokines during TMZ-promoted cellular dormancy exit.

In conclusion, we demonstrated that chemokines play a significant role in the regulation of drug-promoted cellular dormancy entry and exit pointing to a fine-tuning influence of these molecules on distinct cellular dormancy processes in glioblastomas.

Materials and methods

Human specimens

Freshly dissected glioma samples of various malignancy grades were obtained at the Department of Neurosurgery
(Kiel, Germany) in accordance with the Helsinki Declaration of 1975 and with approval of the ethics committee of the University of Kiel, Germany, after written informed consent of the donors (file references: D471/15 and D524/17). The diagnosis was made by the Department of Pathology (UKSH, Kiel, Germany).

**Cultivation of GBM cell lines and human primary GBM cells**

The human glioblastoma cell lines T98G (ECACC No. 92090213) and LN229 (ATCC-CRL-2611) were obtained from the European Collection of Cell Cultures (ECACC, Salisbury, UK) or the American Type Culture Collection (ATCC, Manassas, Virginia, USA) and cultured as described previously [32]. Human primary GBM cultures were produced by dissociation and cultured according to established techniques as previously described [32]. Purity of the GBM cells was ascertained by immunostaining with cell type-specific markers, and by the absence of contamination with mycoplasms, and GBM cell line identity was verified by short tandem repeat profiling as previously described [19].

**Stimulation of GBM cells**

1.5 × 10^5 T98G, LN229, 116/14, or 118/14 cells, respectively, were stimulated for ten days with 500 μM TMZ (Sigma-Aldrich, St. Louis, MO, USA) dissolved in dimethyl sulfoxide (DMSO, Merck, Darmstadt, Germany) in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific). DMSO 0.5% (v/v) was used as control. Medium was changed, and the cells were cultured for a further 15 days without TMZ-stimulation. In addition, 2 nM CXCL12, CXCL16, and CX3CL1 (recombinant human proteins, PeproTech GmbH, Hamburg, Germany) were added individually or as chemokine cocktail. Stimulation with the individual chemokines and with the cocktail was continued during the 15-day period following TMZ-treatment. These experiments were analyzed by reverse transcription and quantitative real-time polymerase chain reaction (qRT-PCR), western blot, and immunocytochemistry after ten days of stimulation, as well as after further 15 days without TMZ-stimulation as described below. The effects of the individual chemokines were proven using LN229 cells with CRISPR/Cas9 knock-out of CXCR7, CXCL16, or CX3CL1, respectively, and in which CXCR4 signaling was specifically inhibited by addition of 10 μM AMD3100 (selective CXCR4 inhibitor, Merck). To prove TMZ-promoted cellular dormancy and recovery, the cells were stained with Vybrant® DiO cell-labeling solution (Thermo Fisher Scientific) according to manufacturer’s instructions, and dye retention was monitored at day 10, as well as at days 7 and 15 after TMZ-stimulation by transmitted light and fluorescence microscopy (AxioObserver.Z1; Carl Zeiss, Oberkochen, Germany) with equal exposure times in relation to controls using the ZEN2 software. Finally, stained and vital cells were counted in every section from each experiment in at least eight different fields of view at 100-fold magnification, and the ratio of stained cells to total number of vital cells was calculated.

**Microarray-based transcriptome analysis**

RNA of differentially treated LN229 cells was isolated with the TRIzol® reagent (Thermo Fisher Scientific). All following steps including microarray-based transcriptome analysis were performed by OakLabs GmbH (Hennigsdorf, Germany) using the ArrayXS® human 8 × 60 K microarray (Agilent Technologies, Santa Clara, CA, USA) that covers 59,508 coding and non-coding genes. In detail, the integrity of RNA samples was assessed using the Bioanalyzer’s RNA integrity number (RIN) to determine the quality and quantity of the samples. For labeling, the low input QuickAmp® labeling kit (Agilent Technologies) was used to generate fluorescent cRNA, and an in vitro transcription was performed to obtain cRNA labeled with cyanine 3-CTP. After hybridization with the Agilent gene expression hybridization kit (Agilent Technologies), fluorescence signals were detected by the SureScan® microarray scanner (Agilent Technologies). Background subtracted signals were quantile normalized using the ranked mean quantiles, and n-fold expression differences were presented after logarithmic base 2 transformation, i.e., log2 (expression ratio) = log2-fold change (log2FC). Negative and positive log2FC values indicate overexpression and downregulation, respectively, in relation to controls, e.g., a log2FC = 2 indicates a 4-fold expression difference. Statistical analysis was performed using Welch’s t-test. Log2FC values between −1 and 1 were not considered, and only statistically significant values (p < 0.05) were displayed. Venn diagrams were prepared to visualize the influence of chemokines on TMZ-promoted cellular dormancy entry and exit. Complete gene lists including log2FC and p values of different Venn areas are given in Supplementary Tables 1 and 2.

**CRISPR/Cas9 gene knock-out**

LN229 cells were seeded into a six-well plate (1.5 × 10^5 cells/well), overlaid with DMEM containing 10% FBS, and the CRISPR/Cas9 plasmid solution (Santa Cruz Biotechnology, Dallas, TX, USA) was added drop-wise according to the manufacturer’s instructions. Transfection was performed overnight at 37 °C. To ensure gene knock-out, successfully transfected clones were selected by their
acquired resistance to puromycin [1 μg/ml puromycin (InvivoGen, San Diego, CA, USA)]. Individual clones were picked, and knock-out efficiency was analyzed by qRT-PCR and immunocytochemistry as described below.

Reverse transcription and quantitative real-time PCR (qRT-PCR)

RNAs of tissues and cells were isolated with the TRIzol® reagent (Thermo Fisher Scientific) or with the ACR-TURUS® PicoPure® RNA isolation kit (Applied Biosystems, Waltham, MA, USA) according to the manufacturer’s instructions. DNase digestion, cDNA synthesis, and qRT-PCR were performed as described previously [19, 33] using TaqMan primer probes (Applied Biosystems) listed in Supplementary Table 3. Cycles of threshold (ĈT) were determined, and the ΔĈT values of each sample were calculated as CTgene of interest − CTGAPDH. ΔĈT values or, for better comparison, linearized ΔĈT values are shown in the figures. The induction of gene expression after stimulation is displayed as n-fold expression changes = 2ΔĈT control − ΔĈT stimulus.

Immunohistochemistry and immunocytochemistry

Cryostat sections of GBM tissues and glass cover slips of differentially treated cells were prepared as described previously [19, 32]. Cells were incubated overnight with the primary antibodies at 4 °C, followed by the secondary antibodies at 4 °C, followed by the secondary reagent (Thermo Fisher Scientific). Primary antibodies were omitted for negative controls. For secondary antibody controls, IgG mouse (MAB002; R&D Systems, Minneapolis, MN, USA) or IgG rabbit (AB-105-C; R&D Systems) control antibodies were used at the same concentrations as the replaced primary antibodies. Donkey anti-mouse or anti-rabbit IgGs labeled with Alexa Fluor 488 or Alexa Fluor 555 (1:1,000; Thermo Fisher Scientific) served as secondary antibodies.

Western blot

Differentially treated cells were harvested, and 3 to 30 μg of protein per sample were used for western blotting as described previously [32]. Used primary antibodies are listed in Supplementary Table 5. Secondary antibodies were donkey anti-rabbit, anti-mouse or anti-goat IgG-HRP (1:40,000, 1:30,000 or 1:100,000; Santa Cruz Biotechnology). As loading control of equal amount of protein, GAPDH was detected as described previously [32]. Signal densities were measured using ImageJ® software. For phosphorylated kinases the signals were normalized to GAPDH, and phospho-p38/phospho-p42/44 ratios were calculated for DMSO-treated and TMZ-treated samples; for CCL2, FSTL3, THSD4, SA2A, and VEGFC the signals were normalized to GAPDH, and the n-fold signal induction was determined in relation to respective control samples (control/chemokine = 1).

Statistical analysis

The data were statistically analyzed using the GraphPad Prism 8.4® software (GraphPad Software, San Diego, CA, USA). To ensure an adequate power to detect a pre-specified effect size, all experiments were performed whenever applicable with a minimum of n = 3 independent biological replicates. Samples were only included in the study if they met established internal quality control criteria, i.e., no mycoplasma contamination, correct short tandem repeat profiling, correct histological diagnosis etc. Depending on the experimental setup either a Student t-test, a one-way analysis of variance (ANOVA) or a two-way ANOVA was performed, as indicated for each experiment in the individual figure legends. The data fulfilled the preconditions of the tests, and the variance between the statistically compared groups was similar. The samples sizes and a description of the sample collection including the number of biological/technical replicates are exactly described in the figure legends. In general, the data are presented as mean ± standard deviation (SD). Statistical significance is marked with asterisks depending on the p value: *p < 0.05, **p < 0.01, and ***p < 0.001.

Acknowledgements We thank Fereshteh Ebrahim, Brigitte Rehmke, and Judith Becker for expert technical assistance. This work was funded by the German Research Foundation (DFG) as part of the Research Training Group “Materials4Brain” (RTG2154; P8) and a sponsorship of the University Medical Center Schleswig-Holstein, UKSH (“Anschubförderung 2020” given to JHF). Open access funding was provided by Projekt DEAL.

Author contributions JHF, KH, and SS conceived and designed the study; VA, JHF, and KH performed the experiments and analyzed the data; CK, GC, RL, MS, and SS contributed materials and data and assisted in data analysis; JHF wrote the paper; all authors revised the manuscript, approved the final version and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.

2. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRα, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.

3. Bonavía R, Inda JM, Cavenee WK, Furnari FB. Heterogeneity in glioblastoma: a social network. Cancer Res. 2011;71:4055–60.

4. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 2013;110:4009–14.

5. Song Y, Zhang Q, Kutlu B, DiFilippantonio S, Bash R, Gilbert D, et al. Evolutionary etiology of high-grade astrocytomas. Proc Natl Acad Sci USA. 2013;110:17933–8.

6. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343:189–93.

7. Senft D, Ronai ZA. Immune, cellular, and angiogenic drivers of tumor dormancy–melanoma view. Pigment Cell Melanoma Res. 2015;28:27–42.

8. Ammerpohl O, Hattermann K, Held-Feindt J, Röcken C, Schäfer F, editors. Ecology and evolution of cancer. Elsevier: Amsterdam; 2017. pp 235–42.

9. Almog N. Molecular mechanism underlying tumor dormancy. Cancer Lett. 2010;294:139–46.

10. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7:834–46.

11. Endaya BB, Lam PY, Meedeniya AC, Neuzil J. Transcriptional profiling of dividing tumor cells detects intratumor heterogeneity linked to cell proliferation in a brain tumor model. Mol Oncol. 2016;10:126–37.

12. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst. 2006;98:316–25.

13. Satchi-Fainaro R, Ferber S, Segal E, Ma L, Dixit N, Ijaz A, et al. Prospective identification of glioblastoma cells generating dormant tumors. PLoS ONE. 2012;7:e44395.

14. Magnus N, Gerges N, Jabado N, Rak J. Coagulation-related gene expression profile in glioblastoma is defined by molecular disease subtype. J Thromb Haemost. 2013;11:1197–2000.

15. Magnus N, Garnier D, Meehan B, McGraw S, Lee TH, Caron M, et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci USA. 2014;111:3544–9.

16. Magnus N, D’Asti E, Meehan B, Garnier D, Rak J. Oncogenes and the coagulation system-forces that modulate dormant and aggressive states in cancer. Thromb Res. 2014;133:1–9.

17. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 2009;69:836–44.

18. Tong L, Yi L, Liu P, Abeyesekera IR, Hai L, Li T, et al. Tumor cell dormancy as a contributor to the reduced survival of GBM patients who received standard therapy. Oncol Rep. 2018;40:463–71.

19. Adamski V, Hempelmann A, Flüh C, Lucius R, Synowitz M, Hattermann K, et al. Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by temozolomide and AT101 treatment. Oncotarget. 2017;8:108064–78.

20. Christofides A, Kosmopoulos M, Piperi C. Pathophysiological mechanisms regulated by cytokines in gliomas. Cytokine. 2015;71:377–84.

21. Lacalle RA, Blanco R, Carmona-Rodriguez L, Martin-Leal A, Mira E, Mañes S. Chemokine receptors signaling and the hallmark of cancer. Int Rev Cell Mol Biol. 2017;331:181–244.

22. Mentlein R, Hattermann K, Held-Feindt J. Migration, metastasis and more: the role of chemokines in the proliferation, spreading and metastasis of tumors. In: Resende R and Ulrich H, editors. Trends in stem cell proliferation and cancer research. Springer-Verlag: Wien-New York; 2013. pp 339–58.

23. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–72.

24. Yao M, Brummer G, Acevedo D, Cheng N. Cytokine regulation of metastasis and tumorigenicity. Adv Cancer Res. 2016;132:265–367.

25. Ehtesham M, Min E, Issar NM, Kasl RA, Khan IS, Thompson RC, et al. The role of the CXCR4 cell surface chemokine receptor in glioma biology. J Neurooncol. 2013;113:153–62.

26. Liu Y, Carson-Walter E, Walter KA. Targeting chemokine receptor CXCR7 inhibits glioma cell proliferation and mobility. Anticancer Res. 2015;35:53–64.

27. Hattermann K, Held-Feindt J, Lucius R, Sebens Müerköster S, Penfold MET, Schall TJ, et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates anti-apoptotic effects. Cancer Res. 2010;70:3299–308.

28. Hattermann K, Mentlein R, Held-Feindt J. CXCL12 mediates apoptosis resistance in rat C6 glioma cells. Oncol Rep. 2012;27:1348–52.

29. Hattermann K, Ludwig A, Gieselmann V, Held-Feindt J, Mentlein R. The chemokine CXCL16 induces migration and invasion of glial precursor cells via its receptor CXCR6. Mol Cell Neurosci. 2008;39:133–41.

30. Held-Feindt J, Hattermann K, Sebens Müerköster S, Wedderkopp H, Knerlich-Lukoschus F, Ungefroren H, et al. CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs). Exp Cell Res. 2010;316:1553–1466.
45. Bruyère C, Mijatovic T, Lonez C, Spiegl-Kreinecker S, Berger W, Nobutani K, Shimono Y, Mizutani K, Ueda Y, Suzuki T, Mallea E, Sodin-Semrlb S, Kovacevica A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci. 2009;66:9.

46. Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001;61:1957–63.

47. Zeng L, Zhao Y, Ouyang T, Zhao T, Zhang S, Chen J, et al. Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, F-polyglycoprotein and CD133 expression. PLoS ONE. 2015;10:e140131.

48. Hiose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001;61:1957–63.

49. Schols D, Struyf S, Van Damme J, Esté JA, Henson G, De Clercq E. Inhibition of T-ropo HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med. 1997;186:1383–8.

50. Yeh AC, Ramaswamy S. Mechanisms of cancer cell dormancy—another hallmark of cancer? Cancer Res. 2015;75:5014–22.

51. Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31:326–41.

52. Clark AM, Wheeler SE, Young CL, Stockdale L, Shepard Neiman J, Zhao W, et al. A liver microphysiological system of tumor cell dormancy and inflammatory responsiveness is affected by scaffold properties. Lab Chip. 2016;17:156–68.

53. Khazali AS, Clark AM, Wells A. Inflammatory cytokine IL-8/CXCL8 promotes tumor escape from hepatocyte-induced dormancy. Br J Cancer. 2018;118:566–76.

54. Nobutani K, Shimono Y, Mizutani K, Ueda Y, Suzuki T, Kitayama M, et al. Downregulation of CXCR4 in metastasized breast tumor cells. Int J Oncol. 2018;19:66–77.

55. Desbaillets I, Tada M, de Tribolet N, Diserens AC, Hamou MF, Van Meir EG. Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. Int J Cancer. 1994;58:240–7.

56. Bowman RL, Joyce JA. Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma. Immunotherapy. 2014;6:663–6.

57. Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Graillon T, et al. Recurrence of glioblastoma after radiochemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway. Oncotarget. 2015;6:11664–75.

58. Hasan T, Caragher SP, Shirereman JM, Park CH, Atashi F, Baissiwala S, et al. Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma. Cell Death Dis. 2019;10:292.

59. Vakilian A, Khorramdelazad H, Heidari P, Rezaei ZS, Hassanshahi G. CCL2/CCR2 signaling pathway in glioblastoma multiforme. Neurochem Int. 2017;103:1–7.

60. Coppola D, Balducci L, Chen DT, Loboda A, Nebozhyn M, Staller A, et al. Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas. J Geriatr Oncol. 2014;5:389–99.

61. Facci L, Barbierato M, Zuzzo M, Skaper SD, Giusti P. Serum amyloid A primes microglia for ATP-dependent interleukin-1β release. J Neuroinflammation. 2018;15:164.

62. Ray A, Yu G-Y, Ray BK. Cytokine-responsive induction of SAF-1 activity is mediated by a mitogen-activated protein kinase signaling pathway. Mol Cell Biol. 2002;22:1027–35.

63. Zhang ZJ, Zhao LX, Cao DL, Zhang X, Gao YJ, Xia C. Curcumin inhibits LPS-induced CCL2 expression via INK pathway in C6 rat astrocytoma cells. Cell Mol Neurobiol. 2012;32:1003–10.

64. Chen L, Liu GQ, Wu HY, Jin J, Yin X, Li D, et al. Monocyte chemoattractant protein 1 and fractalkine play opposite roles in angiogenesis via recruitment of different macrophage subtypes. Int J Ophthalmol. 2018;11:216–22.

65. Guo YC, Zhang M, Wang FX, Pei GC, Sun F, Zhang Y, et al. Macrophages regulate unilateral ureteral obstruction-induced renal lymphangiogenesis through C-C motif chemokine receptor 2-dependent phosphatidylinositol 3-kinase-AKT-mechanistic target of rapamycin signaling and hypoxia-inducible factor-1α/vascular endothelial growth factor-C expression. Am J Pathol. 2017;187:1736–49.

66. Hattermann K, Bartsch K, Gebhardt HH, Mehdrob HM, Synowtitz M, Schmitt AD, et al. “Inverse signaling” of the transmembrane chemokine CXCL16 contributes to proliferative and anti-apoptotic effects in cultured human meningioma cells. Cell Commun Signal. 2016;14:26.

67. Tiram G, Ferber S, Ofek P, Eldar-Boock A, Ben-Shushan D, Yeini E, et al. Reversing the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastoma. FASEB J. 2018;1:fj201701568R.

68. Held-Feindt J, Paredes EB, Blömer U, Seidenbecher C, Stark AM, Mehdrob HM, et al. Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int J Cancer. 2006;118:55–63.

69. Cohen H, Ben-Hamo R, Gidon M, Yitzhaki I, Kozol R, Zilberberg A, et al. Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer. Breast Cancer Res. 2014;16:464.

70. Li J, Ge M, Lu S, Shi J, Li X, Wang M, et al. Pro-inflammatory effects of the Th1 chemokine CXCL10 in acquired aplastic anaemia. Cytokine. 2017;94:45–51.
67. Nie E, Miao F, Jin X, Wu W, Zhou X, Zeng A, et al. Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma. Oncogene. 2019;38:2706–21.
68. Jin X, Nie E, Zhou X, Zeng A, Yu T, Zhi T, et al. Promotes glioma growth through the BMP4/Smad1/5/8 signaling pathway. Cell Physiol Biochem. 2017;44:1616–28.
69. Bartholin L, Guindon S, Martel S, Corbo L, Rimokh R. Identification of NF-kappaB responsive elements in follistatin related gene (FLRG) promoter. Gene. 2007;393:153–62.
70. Bai D, Ueno L, Vog PK. Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt. Int J Cancer. 2009;125:2863–70.